<DOC>
	<DOCNO>NCT00827918</DOCNO>
	<brief_summary>A study evaluate safety efficacy treatment MK-8998 compare placebo olanzapine acutely psychotic patient schizophrenia . The primary hypothesis participant undergo acute psychotic episode schizophrenia , MK-8998 6 8 mg twice daily superior placebo treatment symptom schizophrenia measure mean change baseline Positive Negative Syndrome Scale ( PANSS ) total score Week 4 .</brief_summary>
	<brief_title>A Study Test Safety Efficacy MK-8998 Acutely Psychotic Participants With Schizophrenia ( MK-8998-004 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patient 's age 18 55 Patient meet DSMIV/DSMIVTR criterion primary diagnosis schizophrenia The duration patient schizophrenia diagnosis must great 1 year Patient acute exacerbation psychotic symptom ( least 3 day longer 6 week ) mark deterioration function Patient currently clinically significant neurological , metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , and/or urological disorder would pose risk patient opinion investigator participate study might confound result study The patient evidence acute hepatitis , clinically significant chronic hepatitis , impaired hepatic function The patient chronic organic disease central nervous system ( schizophrenia ) , tumor , inflammation , active seizure disorder , vascular disorder , Parkinson 's disease , Alzheimer 's disease form dementia , myasthenia gravis , degenerative process . In addition , patient must history mental retardation persistent neurological symptom attributable serious head injury Patient history alcohol/drug dependence within 3 month alcohol/drug abuse within 1 month screening . Exceptions include caffeine nicotine abuse/dependence Patient history hypersensitivity olanzapine OR poor response olanzapine last 2 year OR intolerable side effect due olanzapine OR patient current psychotic relapse occur consistently take therapeutic dose ( 10 mg ) olanzapine OR olanzapine medically contradict Patient refractory antipsychotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Acute Exacerbation Schizophrenia</keyword>
</DOC>